Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
about
The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratioHow to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillationLong-term prescribing of new oral anticoagulantsNon-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementationEffectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studySystematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants.Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysisSuboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES studyRecent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation.Time to reconsider dabigatran 110 mg in the USA.Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.Real-world variability in dabigatran levels in patients with atrial fibrillation.Stroke prevention in atrial fibrillation: Where are we now?Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients.Renin-angiotensin blockade in atrial fibrillation: where are we now?Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on CardiovascularDabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.Optimizing stroke prevention in elderly patients with atrial fibrillation.Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review
P2860
Q26776239-C5EEB12A-3837-4C9A-A855-F401FBDA3C7FQ26776413-2B29C9BF-FBD1-41BD-8946-FAA1A15881F8Q28069821-4DA359E7-CA8E-4110-8D29-B7145696CF3BQ28087146-1B17B3C2-54BA-4AA6-9E31-9251ECCE744BQ33647367-A8BDCDB0-1F8D-480A-8FC3-F48729523E20Q35798597-B3087402-C35E-45F2-84F8-D05000C53B47Q36309584-5F153539-E776-4DB8-9CFD-CC2F23115A78Q37226300-28EFD830-D0D9-485C-8B6A-B34E1B040F66Q37577697-939B370D-F189-465F-9145-6F1BF1169D41Q38262325-F02D5B06-AD54-4A8B-A6CD-FA156984C448Q38287155-97DF8DF2-1786-4FC8-95DE-BBDDDB9C3894Q38386660-A3D72A24-6CCA-41EF-80BD-188C1663AFF6Q38526044-1569173C-6199-4EDE-9540-98A40CB8C0DFQ38592125-88201053-7C34-448B-9577-902BF0C57971Q38647787-BF036C1B-8D7A-47DC-A66C-A04575D7B921Q38821650-FD3EFD73-DE91-4D1B-8AA9-DF12DCCC8BEEQ39129273-79AFFEDA-C653-476A-9714-6727E7FA3EBCQ40142501-DB39062D-A84E-4A38-A90E-9E1C14B1CE40Q41438513-339995BF-2EF0-4809-A6AD-D303EBBB07DCQ41671084-229D0827-57E7-41EA-A169-F96567D2EF10Q43119382-04C99B3D-974B-435D-A50A-8042A2411F3CQ45865646-8FAE605C-DD3B-4FE2-BEEE-7509B2CCEEC1Q47114806-739BFEB6-7993-4FE7-BDA2-5313B8EEF3F9Q48318641-87785187-2A6D-4198-9376-084CFA775BF0Q52892786-1C3453F3-118D-4F5E-BA99-F6B691C7353AQ53502627-090D124A-EB45-43CC-BDE4-7433F469B4C3Q53976099-9E89BFBB-910B-4F9F-9882-70D57064E3DDQ58762668-C4BBF9F3-4CB6-419B-910D-786ECE79B6B2
P2860
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@en
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@nl
type
label
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@en
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@nl
prefLabel
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@en
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@nl
P50
P356
P1476
Patient outcomes using the Eur ...... lysis from the RE-LY database.
@en
P2093
Andreas Clemens
Stuart J Connolly
P304
P356
10.1160/TH13-09-0734
P577
2013-12-11T00:00:00Z